| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15941009 | IVR | 55 mg/kg | 55 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 165 mg/kg | 165 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:25554385 | IVR | 0.105 mg/kg/day | 0.105 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.105 mg/kg/day | 0.105 mg/kg/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| PMID:27535158 | IVR | 100 mg/kg/day | 100 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:27581495 | IVTH | 0.00000001 M | 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:28181406 | IVR | 500 mg/kg/day | 500 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:35174924 | IVTH | 0.00006 - 0.0008 M | 0.00006 - 0.0008 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00004 - 0.0008 M | 0.00004 - 0.0008 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:35810903 | IVTH | 0.00025 - 0.001 M | 0.00025 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:36702264 | IVTH | 0.00001 M | 0.00001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 - 0.0005 M | 0.00005 - 0.0005 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:39725349 | IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Increased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 0.03 - 0.3 mg/kg/day | 0.03 - 0.3 mg/kg/day | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.003 - 0.3 mg/kg/day | 0.003 - 0.3 mg/kg/day | Affects thyroid hormone synthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 0.003 - 0.3 mg/kg/day | 0.003 - 0.3 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.